Search

Results 1-10 of 35
Publication DateTitleAuthor(s)
31-Jul-2015Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinomaMatsuo, K; Hasegawa, K; Yoshino, K; Murakami, R; Hisamatsu, T, et al
23-Oct-2015Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerBowtell, DD; Boehm, S; Ahmed, AA; Aspuria, P-J; Bast, RC, et al
19-Oct-2015A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathwayCheraghchi-Bashi, A; Parker, CA; Curry, E; Salazar, J-F; Gungor, H, et al
1-Oct-2015Dose-finding quantitative F-18-FDG PET imaging study with the oral pan-AKT inhibitor GSK2141795 in patients with gynecologic malignanciesGungor, H; Saleem, A; Babar, S; Dina, R; El-Bahrawy, MA, et al
18-Mar-2014A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2 '-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancerGlasspool, RM; Brown, R; Gore, ME; Rustin, GJS; McNeish, IA, et al
12-Jan-2016Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopyKyriakides, M; Rama, N; Sidhu, J; Gabra, H; Keun, HC, et al
22-Dec-2014LARP1 post-transcriptionally regulates mTOR and contributes to cancer progressionMura, M; Hopkins, TG; Michael, T; Abd-Latip, N; Weir, J, et al
4-Oct-2016The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancerAntony, J; Tan, TZ; Kelly, Z; Low, J; Choolani, M, et al
1-Jun-2015The next steps in improving the outcomes of advanced ovarian cancerOpenshaw, MR; Fotopoulou, C; Blagden, S; Gabra, H
6-Nov-2016Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancerAlifrangis, C; Thornton, A; Fotopoulou, C; Krell, J; Gabra, H